

## Special Issue

# New Biomaterials, Delivery Systems and Nanomedicines for Bone Regeneration

### Message from the Guest Editor

For this Special Issue we invite you to submit your innovative basic science and preclinical work in the area of bone regeneration. We are interested in in vitro and in vivo studies that explore and characterize the effects and mechanisms of new biomaterials, delivery systems and nanomedicines on the cellular and molecular level. Topics include but are not limited to functional biomaterials, slow-release systems, delivery systems for osteogenic molecules, nanoparticles, RNA and DNA delivery, viral and non-viral gene therapy, and cell therapy.

---

### Guest Editor

Dr. Volker M. Betz

Musculoskeletal University Center Munich, University Hospital LMU  
Munich, Munich, Germany

---

### Deadline for manuscript submissions

closed (31 December 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.9**  
**CiteScore 6.8**  
**Indexed in PubMed**



[mdpi.com/si/128289](https://mdpi.com/si/128289)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).